SLAMF7/CRACC/CD319 hFc Chimera, Human
SLAMF7/CRACC/CD319 HFc Chimera, Human

Immobilized SLAMF7/CRACC/CD319 hFc Chimera, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 10.7 ng/ml determined by ELISA.

SLAMF7/CRACC/CD319 HFc Chimera, Human

The purity of SLAMF7/CRACC/CD319 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

SLAMF7/CRACC/CD319 HFc Chimera, Human

SLAMF7/CRACC/CD319 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SLAMF7/CRACC/CD319 hFc Chimera, Human

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
Z04282
¥44,770.00

Ask us a question
Product Introduction
Species Human
Protein Construction
SLAMF7/CRACC/CD319 (Ser23-Met226)
Accession # Q9NQ25-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized SLAMF7/CRACC/CD319 hFc Chimera, Human at 0.5μg/ml (100μl/Well) on the plate can bind Biotinylated Anti­SLAMF7 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 49.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • SLAMF7/CRACC/CD319 HFc Chimera, Human
    • SLAMF7/CRACC/CD319 HFc Chimera, Human

    Immobilized SLAMF7/CRACC/CD319 hFc Chimera, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 10.7 ng/ml determined by ELISA.

  • SLAMF7/CRACC/CD319 HFc Chimera, Human
    • SLAMF7/CRACC/CD319 HFc Chimera, Human

    The purity of SLAMF7/CRACC/CD319 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • SLAMF7/CRACC/CD319 HFc Chimera, Human
    • SLAMF7/CRACC/CD319 HFc Chimera, Human

    SLAMF7/CRACC/CD319 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
Synonyms CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.